Cyclosporin A increases recovery after spinal cord injury but does not improve myelination by oligodendrocyte progenitor cell transplantation by Lü, He-Zuo et al.
RESEARCH ARTICLE Open Access
Cyclosporin A increases recovery after spinal cord
injury but does not improve myelination by
oligodendrocyte progenitor cell transplantation
He-Zuo Lü
1,2, Yan-Xia Wang
3, Jian-Sheng Zhou
2, Feng-Chao Wang
4, Jian-Guo Hu
1,2,4*
Abstract
Background: Transplantation of oligodendrocyte precursor cells (OPCs) is an attractive therapy for demyelinating
diseases. Cyclosporin A (CsA) is one of the foremost immunosuppressive agents and has widespread use in tissue
and cell transplantation. However, whether CsA affects survival and differentiation of engrafted OPCs in vivo is
unknown. In this study, the effect of CsA on morphological, functional and immunological aspects, as well as
survival and differentiation of engrafted OPCs in injured spinal cord was explored.
Results: We transplanted green fluorescent protein (GFP) expressed OPCs (GFP-OPCs) into injured spinal cords of
rats treated with or without CsA (10 mg/kg). Two weeks after cell transplantation, more GFP-positive cells were
found in CsA-treated rats than that in vehicle-treated ones. However, the engrafted cells mostly differentiated into
astrocytes, but not oligodendrocytes in both groups. In the CsA-treated group, a significant decrease in spinal cord
lesion volume along with increase in spared myelin and neurons were found compared to the control group. Such
histological improvement correlated well with an increase in behavioral recovery. Further study suggested that CsA
treatment could inhibit infiltration of T cells and activation of resident microglia and/or macrophages derived from
infiltrating monocytes in injured spinal cords, which contributes to the survival of engrafted OPCs and repair of
spinal cord injury (SCI).
Conclusions: These results collectively indicate that CsA can promote the survival of engrafted OPCs in injured
spinal cords, but has no effect on their differentiation. The engrafted cells mostly differentiated into astrocytes, but
not oligodendrocytes. The beneficial effect of CsA on SCI and the survival of engrafted cells may be attributed to
its neuroprotective effect.
Background
Oligodendrocytes are cells that produce myelin in the
central nervous system (CNS). They wrap axons of neu-
rons to produce myelin sheaths, provide trophic support
and protection for neurons and their axons [1,2]. At
least a part of the functional deficit after spinal cord
injury (SCI) is attributable to chronic progressive
demyelination [3]. Therefore, it seems to be an effective
strategy to increase the extent of remyelination by trans-
planting CNS myelin-forming cells into the injured
spinal cord.
Oligodendrocyte precursor cells (OPCs), which are
still bipotential in vitro and can differentiate into mye-
lin-forming cells of the CNS under certain conditions.
As one of the promising candidate cells, OPCs have
been used for treatment of SCI [4-6]. Using a special
culture system, we have induced OPCs from rat
embryonic spinal cord-derived neural precursor cells
(NPCs) [7] and transplanted them into injured spinal
cord. However, our study revealed that after being trans-
planted into the spinal cord, only a small number of the
OPCs could survive, and most of them differentiated
into astrocytes, but not oligodendrocytes. The mechan-
isms which caused to this result may be related to a dis-
advantageous micro-environment in the injured zone
created by lipid peroxidation [8-11], an inflammatory
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grafts [5,14,15], etc.
Cyclosporin-A (CsA) is an immunosuppressive agent
that can depress cellular and humoral immune
responses by inhibiting T helper lymphocyte prolifera-
tion [9,16]. It can also diminish overproduction of free
radicals and lipid peroxidation, which were both
observed after acute SCI. CsA does this by inhibiting
both the inflammatory reaction and the synthesis of
nitric oxide [9,16-20]. Therefore, CsA may act as a neu-
roprotective agent and be useful in the treatment of
acute SCI.
In this study, we transplanted embryonic NPC
derived-OPCs which express green fluorescent protein
(GFP-OPCs) into injured spinal cords of rats treated
with or without CsA, to evaluate whether the drug is
beneficial for survival and differentiation of engrafted
OPCs and plays a neuroprotective role after SCI.
Results
Identification of NPC-induced GFP-OPCs, derived from rat
embryonic spinal cord
GFP-OPCs were cultured for 5 days in different media
as described in Materials and Methods, to assess their
differentiation potential. When oligospheres were tritu-
rated into single cells and plated onto coverslips in
basal-OPC-medium supplied with PDGF-AA and bFGF
(+PDGF, +bFGF), almost all of the cells displayed bipo-
lar or tri-polar morphology, the typical morphology of
OPCs (Fig. 1A). Among them, more than 95% of cells
expressed both A2B5 and PDGFRa ( F i g .1 B ,C ) .I nt h e
presence of T3 without PDGF-AA and bFGF (-PDGF,
-bFGF, +T3), the cells displayed a multi-polar morphol-
ogy (Fig. 1D, G). More than 95% of them expressed RIP
(Fig. 1E, F), and almost no cells expressed GFAP (Fig.
1H, I). In the presence of 10% FBS (-PDGF, -bFGF,
+10%FBS), the cells displayed the typical process-bearing
morphology of astrocytes (Fig. 1J, M). Few cells
expressed RIP (Fig. 1K, L) and nearly all cells expressed
GFAP (Fig. 1N, O).
Effect of CsA on the survival of engrafted OPCs in injured
spinal cord
To investigate the survival of engrafted OPCs in vivo,
we engrafted GFP-OPCs into contusive injured spinal
cord at 10 days after SCI. To investigate whether the
engrafted GFP-OPCs could survive to the end of the
experiment, we detected the engrafted cells by GFP
fluorescence at 2 weeks and 6 weeks after transplanta-
tion. We also determined the effect of CsA on the survi-
val of the engrafted OPCs. The results showed that the
GFP cells could be observed in spinal cords of cell-
transplanted rats at 2 weeks and 6 weeks after trans-
plantation. Because it is extremely difficult to discern
individual cells at 6 weeks, we chose 2 weeks to count
the survived cells and determine their phenotype. Figure
2s h o w st h er e p r e s e n t a t i v ep i c t u r e sf r o mt h es p i n a l
cords after cell transplantation for 2 weeks. Quantitative
analysis showed that the average total number of GFP-
positive cells present in the spinal cord of vehicle con-
trol group and CsA-treated group were 3.02% (12,095 ±
3,364) and 15.77% (63,111 ± 22,149) of the original
injected cell number (4 × 10
5), respectively. There was
statistically significant di f f e r e n c eb e t w e e nt h et w o
groups (p < 0.01, Fig. 2A-C). To examine the prolifera-
tion of transplanted cells, animals received injections of
BrdU before they were sacrificed at 2 weeks after trans-
plantation. We observed few GFP/BrdU-double positive
cells in both vehicle and CsA-treated groups. There was
no statistically significant difference between the two
groups (p > 0.05, Fig. 2D-F). These results collectively
indicate that the increased numbers of GFP-cells were
likely the result of enhanced survival by CsA.
Effect of CsA on differentiation of engrafted OPCs in
injured spinal cord
Next, we investigated whether CsA has any effect on the
differentiation of engrafted OPCs. The differentiation of
engrafted GFP-OPCs in spinal cords from vehicle- and
CsA-treated groups was detected by immunofluores-
cence staining of PDGFRa, GFAP and RIP, respectively.
We found that the most GFP-cells expressed GFAP,
only a very small number of GFP-cells expressed RIP
and almost no GFP-cells expressed PDGFRa in both
groups. Among the total GFP-positive cells, the GFP/
GFAP-double positive cells were 95.00% ± 2.59% and
96.00% ± 1.83% in vehicle- and CsA-treated groups,
respectively. The GFP/RIP-double positive cells were
only 3.33% ± 1.53% and 4.00% ± 1.00% in vehicle- and
CsA-treated groups, respectively. The percentage of
both markers had no statistically significant difference
between the two groups (p > 0.05, Fig. 2G-O).
Effect of OPC transplantation and CsA on infiltration of
CD3
+T cells and activation of resident microglia cells and/
or macrophages derived from infiltrating monocytes in
the injured spinal cords
To observe the effect of CsA on immune responses, we
examined the infiltration of CD3
+T cells, and activation of
resident microglia and/or macrophages derived from infil-
trating monocytes in the injured spinal cord at 2 weeks
after cell transplantation. The CD3, a specific marker of T
lymphocytes, and CD68, a marker of activated resident
microglia and macrophages derived from infiltrating
monocytes were detected by immunofluorescent staining.
The numbers of CD3-positive cells in injured spinal cord
of vehicle- and CsA-treated groups were 3,340 ± 355, and
958 ± 116, respectively, and of the OPC transplantation
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Page 2 of 16Figure 1 Identification and differentiation of GFP-OPCs. The GFP-OPCs induced from spinal cord-derived NPCs were cultured in different
media for 5 days. (A~C): In the basal-OPC-medium containing PDGF and bFGF, the cells display bipolar or tri-polar morphology, the typical
morphology of OPC (A), more than 95% of cells express both A2B5 (B) and PDGFR (C). Inserts show higher power photographs of OPCs. (D~I) In
the medium containing T3 and without PDGF and bFGF, the cells display a multipolar morphology (D, G), more than 95% of the cells express
RIP (E, F), and almost no cells express GFAP (H, I).(J~O) In the medium containing 10%FBS without PDGF and bFGF, the cells display the typical
process-bearing morphology of astrocytes (J, M), few cells express RIP (K, L) and nearly all cells express GFAP (N, O). Cells in B, C, E, F, H, I, K, L, N
and O were counterstained with Hoechst33342 (blue), a nuclear dye. Scale bars: 25 μm.
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Page 3 of 16Figure 2 Survival and differentiation of OPCs after engraftment into the injured adult rat spinal cord for 2 weeks. Two weeks after cell
transplantation, the survival and differentiation of engrafted cells were detected in sagittal sections of injured spinal cord. A, B: Representative
pictures show surviving GFP-cells in the vehicle (A) and CsA (B) treated groups. D, E, G, H, J, K: Representative merged images show GFP/BrdU-
double positive cells (yellow) in the vehicle (D) and CsA (E) treated groups, GFP/GFAP-double positive cells (yellow) in the vehicle (G) and CsA
(H) treated groups, and GFP/RIP-double positive cells (yellow) in the vehicle (J) and CsA (K) treated groups. The statistical graphs show the
number of GFP-cells (C), the percentages of BrdU (F), GFAP (I) and RIP (L) positive cells in GFP-cells. Data are given as means ± SD, n =6 ,* *
p < 0.01 (t test). Scale bar in A, B: 500 μm; in D, E: 20 μm; in G, H, J, and K: 40 μm.
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Page 4 of 16without and with CsA groups were 3261 ± 230, and
1037 ± 191, respectively (Fig. 3). The CD68-positive cells
were 1485 ± 262, 309 ± 97, 1519 ± 328, and 326 ± 83,
respectively (Fig. 4). The numbers of CD3-positive and
CD68-positive cells in CsA-treated groups (with or
without OPC transplantation) were significantly lower
than those of vehicle-treated groups (p < 0.01), while the
OPC transplantation had no effect on the infiltration of T
cells and activation of microglia and/or macrophages
derived from infiltrating monocytes (Fig 3E and Fig 4E).
Figure 3 Infiltration of CD3
+T cells in the injured spinal cords. Two weeks after cell transplantation, immunofluorescence labeling showed
the CD3
+ T cells in injured spinal cords. A~D: Representative pictures show CD3
+ cells in the vehicle (A), CsA (B), GFP-OPC transplantation with
vehicle (C) or with CsA (D) groups. E: The statistical results. Data are given as means ± SD, n =6 ,* *p < 0.01 (ANOVA). Scale bar 20 μm.
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volume of contused spinal cord
Quantitative analysis of the total lesion volume in whole
spinal cords in all groups was performed at the 7
th week
after SCI. In the vehicle-treated group, the total lesion
volume was 15.20% ± 1.97%. In the CsA-treated group,
it was 11.23% ± 1.78%. In OPC transplantation with the
vehicle-treated group, it was 14.89% ± 2.81%. In OPC
transplantation with the CsA-treated group, it was
11.16% ± 1.83%. The total lesion volumes in CsA-
treated groups (with or without OPC transplantation)
were significantly lower than those of vehicle-treated
Figure 4 Activation of microglia and/or macrophages derived from infiltrating monocytes in the injured spinal cords. Two weeks after
cell transplantation, immunofluorescence labeling showed the activated microglia and/or macrophages derived from infiltrating monocytes
(CD68
+) in injured spinal cords. A~D: Representative pictures show CD68
+ cells in the vehicle (A), CsA (B), GFP-OPC transplantation with vehicle
(C) or with CsA (D) groups. E: The statistical results. Data are given as means ± SD, n =6 ,* *p < 0.01 (ANOVA). Scale bar 20 μm.
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Page 6 of 16groups (p < 0.05), while there was no difference between
the two vehicle-treated groups or the two CsA-treated
groups (with or without OPC transplantation) (Fig 5).
These results indicate that CsA treatment can signifi-
cantly decrease spinal cord lesion volume, while OPC
transplantation has no effect.
Effect of OPC transplantation and CsA on the survival of
motoneurons in the ventral horn following SCI
To determine the effect of OPC transplantation and CsA
on neuronal survival, the numbers of ventral horn (VH)
motor neurons at the injury epicenter as well as at 1, 2, 3,
and 4 mm rostral and caudal to the epicenter were
counted at the 7
th week after injury. As shown in Fig 6, in
CsA-treated groups (with or without OPC transplanta-
tion), more residual motor neurons were found in the VH
at 3 and 4 mm rostral and caudal to the lesion epicenter
than in vehicle-treated groups (p <0 . 0 1 ) .H o w e v e r ,t h e
number of motor neurons showed no statistically signifi-
cant difference between the OPC transplantation group
and the corresponding control (p > 0.05).
Effect of OPC transplantation and CsA on myelin
preservation following SCI
To investigate the effect of OPC transplantation and
CsA on myelin preservation, the extent of residual
myelination, stained with Luxol fast blue (LFB), was
examined at the injury epicenter at the 7
th week after a
contusive SCI. Residual myelination was also examined
at 1, 2, 3, and 4 mm rostral and caudal to the injury epi-
center. As shown in Fig 7, the volume of residual myelin
was significantly increased in CsA-treated groups (with
or without OPC transplantation), at the epicenter as
well as at 1, 2 and 3 mm rostral and caudal to the lesion
epicenter compared with that in vehicle-treated groups
(with or without OPC transplantation, p < 0.01 or 0.05).
However, no statistically significant difference was found
in the volume of residual myelin between the OPC
transplantation group and the corresponding control
(p > 0.05).
To verify the LFB results, a subset of sections from
the injury epicenter of the above groups were stained
with toluidine blue. As sho w ni nF i g8 A - D ,t h es p a r e d
myelin was more abundant in the CsA-treated groups
(with or without OPC transplantation) compared with
the vehicle-treated groups (with or without OPC trans-
plantation, Fig 8E, p < 0.01).
Effect of OPC transplantation and CsA on functional
recovery in rats after SCI
To observe the effect of OPC transplantation and CsA
on functional recovery after SCI, the Basso, Beattie, and
Bresnahan (BBB) locomotor rating scale was evaluated
at 1 and 3 days, and then weekly up to 7 weeks. As
shown in Fig 9, all animals scored 21 points before SCI.
At 1 day after SCI, all animals received a score of 0, and
at 3 days, a score under 2. In the following days, the
locomotor performance substantially improved and
reached a plateau at the third week. Starting from the
first week, the BBB scores in CsA-treated groups (with
or without OPC transplantation) were consistently
higher than the other groups. Additionally, the differ-
ences between the CsA-treated groups and the other 2
groups were statistically significant starting from the
third week and continuing until the 7
th week (p <0 . 0 5 ) .
Notably, no statistically significant difference was found
in BBB scores between the OPC transplantation groups
and the corresponding controls (p > 0.05). These results
indicate that the OPC transplantation alone dose not
affect the behavior of SCI rats and that CsA-treatment
can exert some protective effects leading to functional
recovery in SCI rats.
Discussion
After SCI, many axons remain intact but are rendered
useless by loss of their insulating myelin. OPCs are pre-
cursors which can differentiate into myelin-forming cells
o ft h eC N S .W ee x p e c t e dt h a tt h eO P C st r a n s p l a n t e d
into injured spinal cord could differentiate into mature
oligodendrocytes, induce axonal remyelination and
Figure 5 Three-dimensional reconstruction of lesion volumes
at the 7
th week after contusive SCI. A: Representatives of the
three-dimensional reconstruction of a 10 mm spinal cord segment
from each group containing the lesion cavity (green). The spinal
cord contours and white matters are shown in semitransparent
blue, and the gray matter is depicted in gray. B: Data are given as
means ± SD, n =6 ,*p < 0.05 (ANOVA).
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demonstrated that only a small part of the OPCs could
survive, and most of them differentiated into astrocytes.
Almost no oligodendrocytes could be observed after
OPCs were grafted into injured spinal cord. This indi-
cated that the injured spinal cord environment might be
unfavorable for the grafted cell survival and differentia-
tion into oligodendrocytes. Therefore, it is of great sig-
nificance to improve the local microenvironment of
injured spinal cord when the OPCs are grafted.
CsA is one of the foremost immunosuppressive agents
and has widespread use in tissue and cell transplantation
[21-23]. However, it also carries a risk of CNS toxicity
due to the drug-induced death of oligodendrocytes and
neurons [24]. Therefore, whether the drug is beneficial
to survival and differentiation of engrafted NPC-derived
OPCs in injured spinal cord remains unknown. This is a
question about clinical application because any potential
cell transplantation therapy of SCI would require the
use of immunosuppressants, and it is therefore impor-
tant to characterize any effects of these agents might
have on transplanted cells. To clarify this question, we
used CsA immediately after injury rather than at the
time of transplantation. This exposed the cells to an
immunosuppressive environment in which immune
responses, inflammatory reaction and the synthesis of
nitric oxide, which is caused by SCI, could be inhibited
[9,16-20].
We observed the survival, proliferation, and differentia-
tion of engrafted OPCs using GFP expressed-OPCs which
were induced from GFP-NPCs, derived from GFP trans-
genic rat embryonic spinal cord. The immunocytochemistry
Figure 6 Survival of motoneurons in the spinal cord ventral horn (VH) at the 7
th week after contusive SCI. A: Neutral Red staining shows
VH neurons (arrows) from a CsA treated group in a section 8 mm rostral to the epicenter. B~E: Representative pictures show VH neurons (oval-
shaped dotted line) at 3 mm rostral to the injury epicenter in the vehicle (B), CsA (C), GFP-OPC transplantation with vehicle (D) or with CsA (E)
groups. F: Comparison of VH neurons among different groups at various distances from the injury epicenter (0) as well as at 1, 2, 3, 4 mm rostral
(+) and caudal (-) to it. Data are given as means ± SD, n =6 ,* *p < 0.01 (ANOVA). Scale bar in A: 20 μm, in B and C: 200 μm.
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pure and expressed both A2B5 and PDGFRa,t h et w oc o m -
monly used cell surface markers for OPCs [25-27]. They
could proliferate, be passaged, differentiate into oligoden-
drocytes and type-2 astrocytes under certain conditions
in vitro, and showed classical properties of OPCs [26-28].
Next, the in vivo experiments showed that the treatment
of CsA resulted in a dramatic increase in the numbers
of grafted cells in the injuredc o r d .T h i ss u g g e s t e dt h a t
CsA-treatment could enhance the survival of engrafted
GFP-OPCs and/or induce their proliferation in vivo.T o
determine whether CsA contributed to the proliferation of
transplanted cells, we used the BrdU incorporation assay.
We observed few GFP and BrdU-double positive cells in
both vehicle and CsA-treated groups. This result indicated
that the increased numbers of GFP-expressing cells were
likely the result of enhanced survival.
Oligodendrocyte differentiation of engrafted OPCs is
vital for OPC transplantation treatment of SCI. There-
fore, it is of great significance to clarify whether CsA
could affect differentiation of the engrafted OPCs. Thus,
the differentiation of engrafted GFP-OPCs in spinal
cords was detected by immunofluorescent staining.
Unfortunately, we found that the treatment of CsA had
no effect on the differentiation of engrafted cells; the
exact mechanism is still unclear. Therefore, it is of great
significance to clarify the reason behind the phenom-
enon, and seek new approaches to cause the engrafted
OPCs to differentiate into oligodendrocytes rather than
astrocytes.
Some previous studies have reported that the OPCs
isolated directly from embryonic, neonatal and adult
spinal cord, or induced from ES cells could all differ-
entiate into oligodendrocytes after being transplanted
into CNS [4-6,29-32]. However, in this study, using
embryonic NPC-derived OPCs, we found that few oligo-
dendrocytes could be observed and the majority of
engrafted-OPCs differentiated into GFAP-positive astro-
cytes in both vehicle and CsA-treated groups. However,
we have demonstrated that the OPCs derived from
Figure 7 Quantification of residual myelination in injured spinal cords at the 7
th week after contusive SCI. A~D: Representative pictures
show LFB-stained cross-sections of spinal cords taken from the injury epicenter in the vehicle (A), CsA (B), GFP-OPC transplantation with vehicle
(C) or with CsA (D) groups. E: Comparison of residual myelination among different groups at various distances from the injury epicenter. Data
are given as means ± SD, n =6 ,*p < 0.05, ** p < 0.01 (ANOVA).
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in vitro. We consider that the different source of the
OPCs may contribute to the difference between our
results with the previous. In addition to cell source,
there may be other reasons. For example, in this study,
the transplants occurred in animals that had been on
CsA for 10 days, which is unlike other studies. However,
the detailed mechanism still needs to be further
investigated.
To determine whether transplantation of OPCs and/or
CsA-treatment could improve recovery of function after
SCI, morphological and functional assays were per-
formed. To evaluate the neuroprotective effect of CsA
on SCI, we used CsA immediately after injury. Thus,
this could exert its neuroprotective effect as early as
possible and be suitable for clinical application. We
found that in all CsA-treated groups (with or without
OPC transplantation), there was a significant decrease in
spinal cord lesion volume. Additionally, increases in
spared myelin, myelinated axons and neurons were
found compared to the vehicle-treated groups. Such his-
tological improvement correlated well with increase in
Figure 8 Quantification of spared myelin in injured spinal cords at the 7th week after contusive SCI. A-D: Representative
photomicrographs of toluidine blue-stained sections taken from the sites in the middle of lesion border and pial border of vehicle (A), CsA (B),
GFP-OPC transplantation with vehicle (C) or with CsA (D) groups. Spared myelins (arrows) are more abundant in CsA-treated groups (B and D)
compared to the other two groups (A and C). E: Data are given as means ± SD, n =3 ,* *p < 0.01 (ANOVA).
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Page 10 of 16behavioral recovery. However, no histological or beha-
vioral improvement was found in the OPC-transplanted
groups compared to the corresponding control groups.
These results collectively indicate that the application of
CsA may improve myelin preservation. However, it is
also possible that more endogenous OPCs were spared
and remyelination was improved since the CsA was
used immediately after injury.
How does CsA enhance the survival of engrafted
OPCs in injured spinal cord and improve spinal cord
repair? The previous studies demonstrated that CsA is a
selective immunosuppressive agent known for its neuro-
protective properties. The neuroprotective role is
thought to be attributed to inhibit immune responses,
inflammatory reaction and the synthesis of nitric oxide.
By these means, CsA may diminish overproduction of
self-reactive cells, inflammatory cytokines, free radicals
and lipid peroxidation, all of which can be observed
after acute SCI [9,16-20]. Because the disadvantageous
micro-environment in the injured spinal cord may be
triggered by activated microglia and infiltrated lympho-
cytes [33-36], we supposed that the beneficial effect of
CsA on SCI might also be attributed to its effect on
immune cells. Notably, we found that CsA could signifi-
cantly inhibit infiltration of T cells, and activation of
microglia and/or macrophages derived from infiltrating
monocytes in the injured spinal cords. These results
suggest that inhibition of T cell infiltration, microglia
and/or macrophage activation may be an important
cause, which leads to more survival of engrafted OPCs
and improvement of morphological and functional
recovery after SCI.
An important observation in the present study is that
CsA had a protective effect on SCI. This was consistent
with the previous reports [9,16-20], but it seemed to be
paradoxical with the results of Rabchevsky and collea-
gues who used a similar SCI model to test whether CsA
could improve functional outcome and tissue sparing.
Using careful analysis, they showed absolutely no benefit
of CsA on tissue sparing or BBB scores after SCI [37].
However, the CsA administration scheme in their report
was very different from ours. In our study, the animals
received a daily subcutaneous injection of CsA (10 mg/
kg) starting the first day of SCI and continuing until the
end of the experiments. In the report of Rabchevsky and
co-workers, the rats received a bolus i.p. injection of 20
mg/kg CsA 15 min post-injury and continuous CsA
delivery (2.5 mg/day) via an osmotic minipump for only
7 days [37]. Therefore, the differences between their and
our results are possible and understandable. However,
the exact explanation remains to be determined.
Conclusions
In conclusion, our study indicates that CsA can promote
the survival of engrafted OPCs in injured spinal cords,
but has no effect on their differentiation fate. The
engrafted cells mostly differentiate into astrocytes, but
not oligodendrocytes. The beneficial effect of CsA on
Figure 9 BBB test showing effects GFP-OPC transplantation and CsA on functional recovery following SCI. The BBB scores in vehicle,
CsA, GFP-OPC transplantation with vehicle (vehicle + OPCs) or with CsA (CsA + OPCs) groups are compared. Data are given as means ± SD, n =
12, * p < 0.05 (ANOVA).
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to its neuroprotective effect.
Methods
Animals
A total of 76 adult female Sprague-Dawley (SD) rats
(200 ~ 250 g) were used in this study. Among them, 4
green fluorescent protein (GFP) transgenic rats (pro-
vided by Genome Information Research Center, Osaka
University) on gestation day 14.5 were used as the
source of NPCs. The other rats were received contusive
SCI. All surgical interventions and postoperative animal
care were provided in accordance with the Guide for
t h eC a r ea n dU s eo fL a b o r a t o r yA n i m a l s( N a t i o n a l
Research Council, 1996) and the Guidelines and Policies
for Rodent Survival Surgery provided by the Animal
Care and Use Committees of Bengbu Medical College.
Culture of spinal cord-derived GFP-NPCs
Spinal cord-derived GFP-NPCs were prepared according
to the methods of Fu et al [38], with appreciable modifi-
cations. Briefly, embryonic spinal cords were collected
from GFP transgenic E14.5 SD rats. The cells were iso-
lated by mechanical pipetting in Leibovitz’sL - 1 5m e d -
ium (Gibco, Grand Island, N.Y.). The suspension was
filtered through a nylon mesh of 70 μm. After washing,
cells were seeded at a density of 1 × 10
5 cells/ml, and
incubated at 37°C in a humidified 5% CO2-95% air
atmosphere. The culture medium, referred as basal-
NPC-medium, was composed of DMEM/F12 (Gibco),
1% N2 (Gibco), 1% B27 (Gibco), 3 μg/ml heparin
(Sigma, St. Louis, MO), and 2 mM glutamine (Gibco),
supplemented with 20 ng/ml basic fibroblast growth
factor (bFGF, Gibco) and 20 ng/ml epidermal growth
factor (EGF, Sigma). At day 3 or 4, one-sixth of the
basal-NPC-medium was supplemented. The incubation
was extended until day 6, and neurospheres were col-
lected, mechanically dispersed into single cells, and then
passaged.
Induction of GFP-OPCs from GFP-NPCs
The GFP-OPCs induced from GFP-NPCs were prepared
according to our previous methods [7,39]. Briefly, freshly
dissociated spinal cord-derived GFP-NPCs were seeded
at 1 × 10
5/ml in basal-NPC-medium supplemented with
10 ng/ml bFGF and EGF. The cultures were fed every 2
days by removing one third of the volume of NPC-
medium and adding back the same volume of fresh
OPC-medium [basal-NSC-medium containing 0.1%
bovine serum albumin (BSA) and 10 ng/ml biotin
(referred as basal-OPC-medium), supplemented with 10
ng/ml platelet-derived growth factor-AA (PDGF-AA,
Chemicon Inc. Temecula, CA) and 10 ng/ml bFGF].
When the majority of cells in the neurospheres migrated
out and attached to the bottom of the flask, some
necrotic spheres were generated and floated within the
medium. To eliminate the necrotic spheres and frag-
mented cells, the old medium was replaced by fresh
OPC-medium. Cells were cultured for another 5~7 days
and new spheres were generated, which were referred to
as oligospheres. For passaging, the supernatant fluid was
gently removed and cell cultures were incubated with 1
ml Accutase solution (Innovative Cell Technologies,
Inc., San Diego, CA) for 10 min at 37°C. When the cells
started to detach from the bottom of the flask, 3 ml of
Hank’s buffered salt solution (HBSS) was added to each
flask and the cells were detached entirely by gentle agi-
tation. The cell suspension was harvested, gently dis-
persed using a fire-polished Pasteur pipette and then
centrifuged at 134 g for 6 min at room temperature
(RT). Dissociated cells were washed in 6 ml HBSS for 8
min at 134 g. Finally, cells were plated at a density of 2
×1 0
4 cells/cm
2 in OPC-medium. On the 7th day after
plating, new oligospheres were formed and were again
dissociated by Accutase for further passage.
Differentiation of GFP-OPCs
To induce GFP-OPC differentiation, cells were seeded
onto coverslips coated with poly-L-lysine, at a density of
3×1 0
4 cells/coverslip. Three groups were set up: OPC-
medium only (+PDGF, +bFGF), as the OPC control;
OPC-medium without PDGF-AA and bFGF, but with
30 μM tri-iodothyronine (T3, Sigma) (-PDGF, -bFGF,
+T3), for oligodendrocytes differentiation; OPC-medium
without PDGF-AA and bFGF, but with 10% FBS
(-PDGF, -bFGF, +10%FBS), for type 2-astrocytes differ-
entiation. The OPCs in all groups were allowed to dif-
ferentiate for 5 days.
Contusive SCI
Contusive SCI was performed using a New York Univer-
sity Impactor, as described previously [5,40]. In brief, rats
were anesthetized with pentobarbital (50 mg/kg intraperi-
toneally) and received a laminectomy at the T9 level.
After the spinous processes of T7 and T11 were clamped
to stabilize the spine, the exposed dorsal surface of the
cord was subjected to a weight drop injury using a 10 g
r o d( 2 . 5m mi nd i a m e t e r )d r o p p e da tah e i g h to f
12.5 mm. Sham-operated rats were laminectormized
but not contusion. After the injury, the muscles and skin
were closed in layers, and rats were placed in a tempera-
ture-and humidity-controlled chamber. Manual bladder
emptying was performed three times daily until reflex
bladder emptying was established. For CsA treatment, the
animals received a daily subcutaneous injection of cyclos-
porine A (10 mg/kg, Sandimmune; Novartis, East
Hanover, NJ) starting the first day of SCI and continuing
until the end of the experiments [22]. To prevent
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via the drinking water (50~75 mg/kg).
Transplantation procedures
After SCI for 10 days, seventy-two rats were divided into
four groups, including 12 rats as control (vehicle group),
12 rats only treated with CsA (CsA group), 24 rats for
GFP-OPC transplantation without CsA (vehicle + OPCs
group) and 24 rats for GFP-OPC transplantation with
C s A( C s A+O P C sg r o u p ) .T og r a f tG F P - O P C s1 0d a y s
after SCI, rats were anesthetized with pentobarbital (50
mg/kg intraperitoneally), the spinal cord was re-exposed
and a small window was opened in the dura. Four injec-
tions were made at both left and right laterally from mid-
line, 1 mm cranial and caudal to the lesion site, at a
depth of 1.3 mm and 0.6 mm. For cell transplantation,
two microliters of GFP-OPCs (1 × 10
5 cells) in OPC-
medium were injected into each site through a glass
micropipette with an outer diameter of 50~70 μma n d
the tip was sharp beveled to 30~50° at a rate of 0.5 μl/
min, as described by Cao et al [5]. And the microinjec-
tion system is powered by compressed N2. Thus, a total
of 400,000 cells were grafted into each rat. The muscle
and skin were sutured and normal saline and antibiotics
administered to prevent dehydration and infection. The
animals were sacrificed at 2w or 6w post-transplantation.
Immunocytochemistry
Immunostaining assay for differentiated cells was per-
formed as described previously [7,39]. Antibodies against
A2B5 (IgM, 1:100, R&D, Minneapolis, MN), platelet
derived growth factor alpha receptor (PDGFRa, 1:100,
Neomarkers, Fremont, CA), receptor interaction protein
(RIP, 1:25, a gift from Dr. Scott R. Whittemore, Univer-
sity of Louisville) and glial fibrillary acidic protein
(GFAP, 1:200, Sigma) were used to identify OPCs, oligo-
dendrocytes and astrocytes, respectively [12,26,27,41].
Immunohistochemical assay
Two weeks after cell transplantation, the animals were
given an overdose of sodium pentobarbital (nembutal;
80 mg/kg, i.p.) and were transcardially exsanguinated
with 200 ml physiological saline followed by fixation
with 300 ml of ice-cold 4% paraformaldehyde in 0.01 M
PBS (pH 7.4). After perfusion, a 2 cm spinal cord seg-
ment containing the injury epicenter was removed, post-
fixed overnight in 4% paraformaldehyde in 0.01 M PBS
(pH 7.4), and transferred to 30% sucrose in 0.01 M PBS
(pH 7.4) overnight at 4°C. After that the specimen was
blocked into segments spaced in 5 mm, from the cervi-
cal to the sacral cord. The segments were placed
in OCT compound embedding medium (Tissue-Tek,
Miles, Elkart, IN, USA) and frozen sections of 20 μm
thickness were obtained horizontally or transversely
using a cryostat (Leica CM1900, Bannockburn, IL,
USA), then thaw-mounted on poly-L-lysine-coated slides
(Sigma). For immunohistochemistry, the sections were
blocked with 10% normal goat serum (NGS) in 0.01 M
PBS (pH 7.4) for 60 min, and monoclonal mouse anti-
RIP (1:25), anti-GFAP (1:200), anti-CD3 (1:100; SeroTec,
Inc, Raleigh, NC, USA) or anti-CD68(ED1) antibody
(1:100; SeroTec, Inc) were applied to the sections over-
night at 4°C. On the following day, the sections were
incubated for 60 min at 37°C with rhodamine-conju-
gated goat anti-mouse (1:50; Jackson Immuno Research
Lab., West Grove, PA, USA) antibodies, and slides were
washed, coverslipped, and examined using an Olympus
BX60 microscope.
In both immunocytochemistry and immunohisto-
chemistry assays, primary antiserum omission controls
and normal mouse and goat serum controls were used
to confirm the specificity of the immunofluorescence
labeling.
Cell quantification on the spinal cord tissue of trans-
planted rats was performed in an unbiased stereological
manner as described previously [22]. For quantification
of cell survival, the total number of GFP-expressing/
Hoechst33342-positive cells was counted. Based on our
microscopic examination, the size of the cell body
(including nucleus) of a grafted GFP-OPC is between 10
and 20 μm. To avoid counting the same cell in more
than one section, we counted every fifth section (100
μm apart). We only quantified the GFP cell bodies that
contained a nucleus (identified with Hoechst33342). To
quantify the differentiation pattern of transplanted cells,
we counted the number of GFP-positive cells that were
double-labeled with a different cell marker. For quantifi-
cation of double-positive cells, we chose the spinal cord
sections with the highest number of GFP-positive cells.
For each cell marker, we stained two tissue sections per
rat (at least 100 μm apart). Then we counted the num-
ber of GFP and cell marker double-positive cells in 10
random fields per section. On average, 200 - 300 cells
were counted per section. For quantification of micro-
glia/macrophages and T cells, the number of positive
cells was counted in 10 random fields per section. Two
sections from the epicenter spaced ~100 μma p a r tw e r e
analyzed for each animal and then averaged. Data are
expressed as cell number per square millimeter. For
quantification of aggregated microglia/macrophages, we
identified the individual microglia/macrophages by each
anatomically demarcated nucleus with the help of com-
puter interfaced digital image analysis system. Only the
cell bodies were taken into account.
Histological analyses
Eight weeks after SCI, the animals were sacrificed
as above. Histological analyses were performed as
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blocked into 10 mm segments, serial 20-μm-thick sec-
tions through the entire injury site were cut transversely.
Two sets of slides (each set containing serial sections
spaced 200 μm apart) were stained with Luxol fast blue
(LFB), Neutral Red, respectively, to identify myelinated
white matter and residual ventral horn motoneurons.
The lesion epicenter was defined as the section contain-
ing the least amount of spared white matter. The total
and cross sectional area of the spinal cord and the lesion
boundary were measured with an Olympus BX60 micro-
scope attached to a Neurolucida system (Microbright-
field Inc., Colchester, VT, USA). An unbiased estimation
of the percentage of spared tissue was calculated using
the Cavalieri method [42]. The total volume of the
lesion area (which included areas of cavitation) was cal-
culated by summing their individual subvolumes [43].
Individual subvolumes of the lesion area were calculated
by multiplying the cross-sectional area (A) × D, where
D represents the distance between sections (200 μm).
The percentage total volume of the injured area was cal-
culated by dividing the total volume of lesion area by
the total spinal cord volume [5]. LFB and Neutral Red
-stained sections at the lesion epicenter and 1, 2, 3, and
4 mm rostral and caudal to the epicenter were analyzed
for myelinated white matter and residual ventral horn
motoneurons, respectively. The myelinated white matter
was quantified by Image pro-plus 5.1 (Media Cyber-
netics, Inc, Atlanta, GA, USA) and the number of sur-
viving ventral horn neurons were confirmed by the
exhibition of Nissl substance, euchromatic nucleus and
nucleolus [44].
Toluidine blue staining
The toluidine blue staining was performed as described
previously [40]. In brief, spinal cord segments were fixed
overnight in the solution containing 2% glutaraldehyde
and 5% sucrose in 0.1 M sodium cacodylate buffer, pH
7.4, followed by 1% osmium tetroxide in the same buffer
for 1 h. The tissue was embedded in Spurr’s epoxy resin
and cured at 70°C. Transverse semithin sections (1 μm)
were stained with a mixture of 1% toluidine blue and
1% sodium borate. For statistical analysis, the numbers
of spared myelins were calculated in four random 10 ×
40-fold microscope views (about 67,500 μm
2 per view)
in the middle of lesion border and pial border.in the
dorsal, lateral, and ventral columns.
BBB locomotor rating scale
Behavioral assessments were performed using the Basso,
Beattie, and Bresnahan (BBB) locomotor rating scale, a
21-point scale (0~21) based on the observation of hind-
limb movements of a rat freely moving in an open field
[45,46]. The BBB was evaluated at 1, 3 days, 1, 2, 3, 4, 5,
6 and 7 weeks after injury. During the evaluation, ani-
mals were allowed to walk freely on the open-field sur-
face for 4 min while being observed by two scorers
lacking knowledge of the experimental groups.
In vivo 5-Bromo-2-deoxyuridine (BrdU) incorporation
labelling and detection
Rats received 9 injections of BrdU (50 mg/kg, i.p.; three
injections per day for 3 days) and were sacrificed 2
hours after the last injection. The animals were perfused
transcardially, and tissues were collected as described
above. Then, the slides were processed for immunos-
taining against the BrdU antibody. The sections were
washed with PBS, incubated in 2N HCl and 1% Triton
X-100 for 15 min at room temperature, and washed
with 0.1 M sodium borate in PBS for 10 min. The slides
were blocked with 1% BSA, 5% non-fat milk, and 0.3%
Triton X-100 in PBS for 1 hour at room temperature
and incubated with a mouse anti-BrdU antibody (1:100;
BD Bioscience, Franklin Lakes, NJ) in the same blocking
solution for overnight at 4°C. The slides were treated
with rhodamine-conjugated goat anti-mouse antibody as
described above. The images were taken using an Olym-
pus BX60 microscope.
Statistical analyses
For BBB locomotor rating scale, the data were analyzed
by two-way repeated measures ANOVA followed by
post-hoc analyses. For the other data, the paired data
were analyzed by two-tailed Student’s t-test, the data
with three or more samples were analyzed by one way
ANOVA followed by Student-Newman-Keuls tests of
multiple comparisons to determine whether there were
significant differences between individual groups. All dif-
ferences were considered significant at p < 0.05.
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